

## Agreement Termination Notice of Molnupiravir Sublicense

To: General Counsel of Medicines Patent Pool of Geneva, Switzerland

Dear Sir/Madam,

First of all, we thank you very much for giving us the opportunity to participate in the fight against COVID-19. After Molnupiravir sublicense was granted to us, we have invested a lot to develop the drug substance, in order to supply to public as soon as possible. Now we are very glad to see the COVID-19 Pandemic is ended, the demand and necessity of Molnupiravir does not exist anymore, so after internal discussion, we decided to stop further R&D work on Molnupiravir. So hereby we are regretfully to inform you that we apply to terminate the License Agreement of Molnupiravir, dated 10<sup>th</sup> Jan. 2022, signed between Zhejiang Langhua Pharmaceutical Co.,Ltd and THE MEDICINES PATENT POOL FOUNDATION.

We thank you very much for the kind support on this project and look forward to new collaboration in future.

Yours sincerely

Zhejiang Langhua Pharmaceutical Co.,Ltd

Signature: 

Name: Ji Shengbao

Titel: BD Director

Date: 28<sup>th</sup> Nov 2023